用于 COVID-19 的当前和未来纳米颗粒疫苗。
Current and future nanoparticle vaccines for COVID-19.
机构信息
Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3000, Australia; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, VIC 3052, Australia; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia; Department of Pharmaceutics, Hanoi University of Pharmacy, Hanoi 10000, Vietnam.
Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC 3000, Australia; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, VIC 3052, Australia.
出版信息
EBioMedicine. 2021 Dec;74:103699. doi: 10.1016/j.ebiom.2021.103699. Epub 2021 Nov 19.
COVID-19 has become a major cause of global mortality and driven massive health and economic disruptions. Mass global vaccination offers the most efficient pathway towards ending the pandemic. The development and deployment of first-generation COVID-19 vaccines, encompassing mRNA or viral vectors, has proceeded at a phenomenal pace. Going forward, nanoparticle-based vaccines which deliver SARS-CoV-2 antigens will play an increasing role in extending or improving vaccination outcomes against COVID-19. At present, over 26 nanoparticle vaccine candidates have advanced into clinical testing, with ∼60 more in pre-clinical development. Here, we discuss the emerging promise of nanotechnology in vaccine design and manufacturing to combat SARS-CoV-2, and highlight opportunities and challenges presented by these novel vaccine platforms.
COVID-19 已成为全球死亡的主要原因，并导致大规模的卫生和经济混乱。大规模的全球疫苗接种为结束大流行提供了最有效的途径。第一代 COVID-19 疫苗（包括 mRNA 或病毒载体）的开发和部署进展迅速。未来，基于纳米颗粒的疫苗将在提供 SARS-CoV-2 抗原方面发挥越来越重要的作用，以改善或延长 COVID-19 的疫苗接种效果。目前，已有超过 26 种纳米颗粒疫苗候选物进入临床测试阶段，还有约 60 种处于临床前开发阶段。在这里，我们讨论了纳米技术在疫苗设计和制造方面对抗 SARS-CoV-2 的新兴前景，并强调了这些新型疫苗平台带来的机遇和挑战。
Zotero 插件